Major histocompatibility complex class I-restricted infiltration and destruction of pancreatic islets by NOD mouse-derived beta-cell cytotoxic CD8(+) T-cell clones in vivo

被引:51
作者
Utsugi, T
Yoon, JW
Park, BJ
Imamura, M
Averill, N
Kawazu, S
Santamaria, P
机构
[1] UNIV CALGARY,FAC MED,DEPT MICROBIOL & INFECT DIS,CALGARY,AB T2N 4N1,CANADA
[2] UNIV CALGARY,FAC MED,JULIA MCFARLANE DIABET RES CTR,CALGARY,AB T2N 4N1,CANADA
[3] GUNMA UNIV,SCH MED,DEPT INTERNAL MED 2,GUNMA,JAPAN
关键词
D O I
10.2337/diabetes.45.8.1121
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
NOD mouse-derived beta-cell-specific cytotoxic T-cell (beta-CTL) clones are diabetogenic in adult NOD mice, but only if co-injected with splenic CD4(+) T-cells from diabetic animals, This investigation was initiated to determine whether infiltration of pancreatic islets by beta-CTL is a major histocompatibility complex (MHC) class I-restricted response, and whether beta-CTL has a direct cytopathic effect on beta-cells in vivo. Pancreatic islets from BALB/c (H-2(d)) or B6 (H-2(b)) mice were transplanted under the renal capsule of streptozotocin (STZ)-induced diabetic (NOD x BALB/c) F1 (H-2K(d), H-2D(d,b)) or (NOD x B6) F1 (H-2K(d,b), H-2D(b)) mice, respectively, H-2K(d)-restricted beta-CTL clones from NOD mice were transfused into euglycemic mice within 3 days after transplantation. In all of the H-2(d) islet-grafted (NOD x BALB/c) F1 mice that received the beta-CTL clones, the beta-CTLs homed into the grafts, recruited host Mac-1(+) cells and CD4(+) and CD8(+) T-cells, and caused diabetes within 7 days, In contrast, none of the H-2(b) islet-grafted (NOD x B6) F1 mice who received the beta-CTL clones and none of the H-2(d) islet-grafted (NOD x BALB/c) F1 mice who received a non-beta-cell cytotoxic CTL clone (N beta-CTL) developed graft. inflammation or diabetes, Depletion of CD4(+) T-cells in H-2(d) islet-grafted (NOD x BALB/c) F1 mice did not prevent beta-CTL clone-induced diabetes but reduced its severity. In contrast, when the beta-CTL clones were injected >8 days after transplantation, none of the H-2(d) islet-grafted (NOD x BALB/c) F1 mice became diabetic or developed graft inflammation, We conclude that (1) islet-derived beta-CTLs can destroy beta-cells in vivo; (2) infiltration of grafted islets by beta-CTLs is an MHC class I-restricted response; (3) beta-CTLs can recruit naive CD4(+) T-cells to the site, leading to further beta-cell damage; and (4) revascularized islet grafts are, Like pancreatic islets of irradiated adult NOD mice, ''sequestered'' from circulating beta-CTLs.
引用
收藏
页码:1121 / 1131
页数:11
相关论文
共 36 条
[1]  
ANDO K, 1994, J IMMUNOL, V152, P3245
[2]  
ANDO K, 1994, J IMMUNOL, V153, P482
[3]   SYNGENEIC TRANSFER OF AUTOIMMUNE DIABETES FROM DIABETIC NOD MICE TO HEALTHY NEONATES - REQUIREMENT FOR BOTH L3T4+ AND LYT-2+ T-CELLS [J].
BENDELAC, A ;
CARNAUD, C ;
BOITARD, C ;
BACH, JF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (04) :823-832
[4]   ALPHA-4 INTEGRINS MEDIATE LYMPHOCYTE ATTACHMENT AND ROLLING UNDER PHYSIOLOGICAL FLOW [J].
BERLIN, C ;
BARGATZE, RF ;
CAMPBELL, JJ ;
VONANDRIAN, UH ;
SZABO, MC ;
HASSLEN, SR ;
NELSON, RD ;
BERG, EL ;
ERLANDSEN, SL ;
BUTCHER, EC .
CELL, 1995, 80 (03) :413-422
[5]   INVIVO ACTIVITY OF AN ISLET-REACTIVE T-CELL CLONE [J].
BRADLEY, BJ ;
WANG, Y ;
LAFFERTY, KJ ;
HASKINS, K .
JOURNAL OF AUTOIMMUNITY, 1990, 3 (04) :449-456
[6]   CD8 T-CELLS ARE NOT REQUIRED FOR ISLET DESTRUCTION INDUCED BY A CD4+ ISLET-SPECIFIC T-CELL CLONE [J].
BRADLEY, BJ ;
HASKINS, K ;
LAROSA, FG ;
LAFFERTY, KJ .
DIABETES, 1992, 41 (12) :1603-1608
[7]  
CAMPBELL IL, 1988, J IMMUNOL, V141, P2325
[8]   ADOPTIVE TRANSFER OF DIABETES INTO IMMUNODEFICIENT NOD-SCID SCID MICE - RELATIVE CONTRIBUTIONS OF CD4+ AND CD8+ T-CELLS FROM DIABETIC VERSUS PREDIABETIC NOD.NON-THY-1A DONORS [J].
CHRISTIANSON, SW ;
SHULTZ, LD ;
LEITER, EH .
DIABETES, 1993, 42 (01) :44-55
[9]   A HIGHLY SENSITIVE CELL-LINE, WEHI-164 CLONE 13, FOR MEASURING CYTOTOXIC FACTOR TUMOR-NECROSIS-FACTOR FROM HUMAN-MONOCYTES [J].
ESPEVIK, T ;
NISSENMEYER, J .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (01) :99-105
[10]  
FAVEEUW C, 1994, J IMMUNOL, V152, P5969